SQZ Biotechnologies Announces $2 Million Grant From the National Institutes of Health to Develop a Novel, Scalable Cell Replacement Therapy for…

WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies (NYSE: SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today announced that it has been awarded a $2 million SBIR Phase II grant from the National Institute of General Medical Sciences, a division of the National Institutes of Health. Awarded through a competitive process, the two-year grant will support the development of cell engineering methods that are designed to reprogram a patients own immune cells directly into dopamine-producing neurons, a potential novel therapeutic approach for the treatment of Parkinsons disease.

Directly creating dopamine-producing neurons by reprogramming a patients own immune cells would be a major breakthrough and could support a new Parkinsons disease treatment paradigm, said Jonathan Gilbert, Ph.D., Vice President and Head of Exploratory Research at SQZ Biotechnologies. Unlike alternative allogeneic cell replacement approaches in development for Parkinsons disease, by using a patients own cells, treatment might not require chronic immunosuppression. Moreover, in altering cell fate with RNA-based cell engineering methods, no changes to the genome are likely to occur that could carry long-term risks.

Reprogramming a patients cells to replace lost or diseased cells has significant therapeutic potential. Beyond Parkinsons Disease, applications for cell replacement therapies include Multiple Sclerosis and Type 1 diabetes. However, traditional expensive, time-intensive, and inefficient cell reprogramming methods has hindered clinical progress and patient impact.

At the 2021 International Society for Stem Cell Research annual meeting, the company presented preclinical data showing that proprietary Cell Squeeze technology can be used to generate neurons from induced human pluripotent stem cells through the delivery of an mRNA encoding for a fate-specifying transcription factor.

With the support of the NIH grant, and building upon our experience in multiplex engineering of immune cells, SQZ researchers will attempt to generate dopaminergic neurons directly from somatic cells. The Cell Squeeze technology may allow for a unique complex combination of transcription factors, dosing, and timing.

About SQZ Biotechnologies SQZ Biotechnologies Company is a clinical-stage biotechnology company focused on unlocking the full potential of cell therapies for patients around the world and has active programs in Oncology, Autoimmune and Infectious Diseases, as well as additional exploratory initiatives to support future pipeline growth. The companys proprietary Cell Squeeze technology offers the unique ability to deliver multiple biological materials into many cell types to engineer what we believe can be a broad range of potential therapeutics. With demonstrated production timelines under 24 hours and the opportunity to eliminate preconditioning and lengthy hospital stays, our approach could significantly broaden the therapeutic range and accessibility of cell therapies. The companys first therapeutic applications seek to generate target-specific immune responses, both in activation for the treatment of solid tumors and infectious diseases, and in immune tolerance for the treatment of autoimmune diseases. For more information, please visit http://www.sqzbiotech.com.

Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements relating to events our platform development, our product candidates, project funding, preclinical and clinical activities, progress and outcomes, development plans, manufacturing, clinical safety and efficacy results, therapeutic potential, market opportunities and disease prevalence. These forward-looking statements are based on management's current expectations. Actual results could differ from those projected in any forward-looking statements due to several risk factors. Such factors include, among others, risks and uncertainties related to our limited operating history; our significant losses incurred since inception and expectation to incur significant additional losses for the foreseeable future; the development of our initial product candidates, upon which our business is highly dependent; the impact of the COVID-19 pandemic on our operations and clinical activities; our need for additional funding and our cash runway; the lengthy, expensive, and uncertain process of clinical drug development, including uncertain outcomes of clinical trials and potential delays in regulatory approval; our ability to maintain our relationships with our third party vendors and strategic collaborators; and protection of our proprietary technology, intellectual property portfolio and the confidentiality of our trade secrets. These and other important factors discussed under the caption "Risk Factors" in our Annual Report on Form 10-K, as updated by our Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2021 and other filings with the U.S. Securities and Exchange Commission could cause actual results to differ materially from those indicated by the forward-looking statements. Any forward-looking statements represent management's estimates as of this date and we undertake no duty to update these forward-looking statements, whether as a result of new information, the occurrence of current events, or otherwise, unless required by law.

Certain information contained in this press release relates to or is based on studies, publications, surveys and other data obtained from third-party sources and our own internal estimates and research. While we believe these third-party sources to be reliable as of the date of this press release, we have not independently verified, and we make no representation as to the adequacy, fairness, accuracy or completeness of any information obtained from third-party sources.

Read the original here:
SQZ Biotechnologies Announces $2 Million Grant From the National Institutes of Health to Develop a Novel, Scalable Cell Replacement Therapy for...

Impact of maintenance therapy post autologous stem cell transplantation for multiple myeloma in early and delayed transplant – Newswise

Based on phase 3 trials, maintenance therapy after autologous stem cell transplantation (ASCT) has become the standard of care in multiple myeloma (MM). We examined the trends in maintenance therapy in a large group of patients (2530) transplanted at a single institution over two decades. Majority (n=1958; 77%) had an ASCT within 12 months of diagnosis (early ASCT). Maintenance was employed in 39% of the patients; 42% among early ASCT and 30.5% among delayed ASCT. Most common maintenance approach was an IMiD (61%), followed by a PI (31%), or a PI+IMiD (4%). Patients with high-risk FISH received PI-based maintenance more frequently. The PFS was superior with maintenance (36 vs. 22 months,p<0.001); 37 vs. 25 months for early ASCT (p<0.001) and 29 vs. 17 months for delayed ASCT (p=0.0008). OS from ASCT was higher with maintenance for the whole cohort at 93 vs. 73 months (p<0.001). OS from diagnosis was also better for the whole cohort with maintenance therapy, 112 vs. 93 months (p<0.001). The improvement in PFS and OS was seen in high-risk and standard risk disease. The experience with maintenance therapy post ASCT for myeloma in a non-clinical trial setting confirms the findings from the phase 3 trials.

Read the original:
Impact of maintenance therapy post autologous stem cell transplantation for multiple myeloma in early and delayed transplant - Newswise

iTolerance, Inc. Closes $17.1 Million Convertible Note Financing to Advance Development of Innovative Regenerative Medicines for Transplantation…

The Company's proprietary biotechnology-derived Strepavidin-FasL fusion protein/biotin-PEG microgel platform technology, iTOL-100, has demonstrated in animal models of Type 1 Diabetes the ability to induce local immune tolerance and allow long-term engraftment of insulin-producing allogenic pancreatic islet cells without the need for chronic life-long immunosuppression

Lead program, iTOL-101, being developed as a potential breakthrough in curing Type 1 Diabetes

Second lead program, iTOL-102, is also being developed as another potential breakthrough in curing Type 1 Diabetes leveraging stem cell derived pancreatic islet

MIAMI, FL / ACCESSWIRE / March 21, 2022 / iTolerance, Inc. ("iTolerance" or the "Company"), an early stage regenerative medicine company developing technology to enable tissue, organoid or cell therapy without the need for life-long immunosuppression, today announced the closing of its convertible note financing in which the Company raised a total of approximately $17.1 million in gross proceeds. The Company plans to use proceeds from the financing to translate the production of iTOL-100 from the academic labs to commercial manufacturing for use in its planned pre-clinical and clinical trials and for other general corporate purposes.

"As a start-up life sciences company, raising $17.1 million is a noteworthy endorsement from investors and bolsters our confidence in the potential of our proprietary platform technology. With this capital in hand, we are focused on executing next steps in de-risking our manufacturing processes and positioning ourselves to successfully advance into and through pre-clinical studies to support a Phase 1/2 clinical study for iTOL-101," commented Dr. Anthony Japour, Chief Executive Officer of iTolerance. "We believe our platform technology is a potential game changer for patients with Type 1 Diabetes and the physicians who treat them. Additionally, this technology can be applied to a number of cellular therapies for chronic conditions."

Story continues

The Company's iTOL-100 platform technology is a biotechnology-derived Strepavidin-FasL fusion protein, a synthetic form of the naturally occurring protein FasL, mixed with a biotin-PEG microgel (SA-FasL microgel) that potentially allows convenient and effective co-administration with implanted cells or organoids to induce local immune tolerance without the need for life-long immunosuppression. In pre-clinical studies, iTOL-100 has been shown to establish durable, localized immune tolerance, allowing the implanted tissue, organoid or cell therapy to function as a replacement for damaged native cells.

iTolerance's lead program iTOL-101 is being developed as a potential cure for Type 1 Diabetes. Using the iTOL-100 platform technology, allogenic pancreatic islets are co-implanted and in pre-clinical studies have shown immune acceptance and long-term function of the graft with control of blood glucose levels and restoration of insulin secretion without the need for immunosuppression. The Company is moving forward with pre-clinical studies to support a Phase 1/2 study in Type 1 Diabetes.

The Company's second lead program, iTOL-102, utilizes the iTOL-100 platform technology to induce local immune tolerance and leverages significant advancements in stem cell-derived pancreatic islets which allows an inexhaustible supply of insulin-producing cells as a potential cure for Type 1 Diabetes without the need for life-long immunosuppression.

About iTolerance, Inc.

iTolerance is an early stage privately held regenerative medicine company developing technology to enable tissue, organoid or cell therapy without the need for life-long immunosuppression. Leveraging its proprietary biotechnology-derived Strepavidin-FasL fusion protein/biotin-PEG microgel (SA-FasL microgel) platform technology, iTOL-100, iTolerance is advancing a pipeline of programs using both allogenic pancreatic islets and stem cells that have the potential to cure diseases. The Company's lead program, iTOL-101 is being developed for Type 1 Diabetes and in a pre-clinical non-human primate study, pancreatic islet cells co-implanted with iTOL-101 exhibited long-term function with control of blood glucose levels and restoration of insulin secretion without the use of chronic immune suppression. The Company's second lead candidate, iTOL-102, is leveraging significant advancements in stem cells to derive pancreatic islets which allows an inexhaustible supply of insulin-producing cells. Utilizing iTOL-100 to induce local immune tolerance, iTOL-102 has the potential to be a cure for Type 1 Diabetes without the need for life-long immunosuppression. Additionally, the Company is developing iTOL-201 for liver failure and iTOL-301 as a potential regenerative protein and cell therapy that leverages stem cell sources to produce proteins or hormones in the body in conditions of high unmet need without the need for life-long immunosuppression. For more information, please visit itolerance.com.

Investor Contact Jenene Thomas Chief Executive Officer JTC Team, LLC T: 833.475.8247 iTolerance@jtcir.com

SOURCE: iTolerance, Inc.

View source version on accesswire.com: https://www.accesswire.com/693757/iTolerance-Inc-Closes-171-Million-Convertible-Note-Financing-to-Advance-Development-of-Innovative-Regenerative-Medicines-for-Transplantation-Without-the-Need-for-Life-Long-Immunosuppression

Originally posted here:
iTolerance, Inc. Closes $17.1 Million Convertible Note Financing to Advance Development of Innovative Regenerative Medicines for Transplantation...

‘Without you there is no cure’ – Teenager’s call for stem cell donors in mission to support Anthony Nolan Trust – Shields Gazette

Abbie Young was 16 when she was given the devastating news that her body was suffering from severe Aplastic Anaemia.

With her bone marrow failing, medics at Newcastles Royal Victoria Infirmary Ward 3 were in a race against time to find a stem cell donor who could give her a fighting chance.

Abbie, now 18, is on the road to recovery thanks to the Anthony Nolan Trust.

To say thank you for saving her life, the Harton Academy pupil is aiming to help boost the charitys work by hosting a fundraising day at school on Friday, April 8.

Abbie, who hopes to become an Anthony Nolan youth ambassador, is aiming to encourage others to sign up as stem cell donors and help save lives.

She said: I just feel really grateful that someone out there took the time to sign up to the stem cell register and that one choice someone made, has saved my life.

I know some kids die waiting for a donor, so I will always be forever grateful for what my donors did and to the Anthony Nolan Trust.

Read More

The teenager discovered her bone marrow was failing her after her mum became concerned over the number of bruises her daughter had. Abbie was diagnosed in January 2020.

Mum Caroline, 49, said: We went to the doctors who sent Abbie to South Tyneside Hospital for blood tests.

Abbie was at the hospital on the Friday (January 10), then by Saturday morning we had a knock on the door and there was an ambulance outside, they had come for Abbie.

They took us to Sunderland hospital and her dad followed up in the car, where they did more tests, they thought she had leukaemia, so we were transferred straight to the RVI.

According to information from Great Ormond Street Hospital, severe Aplastic Anaemia only affects around 30 to 40 children in the UK each year.

After Abbies older siblings, brother Sam, 26, and sister Kate, 21, were found not to be matches, a donor from Germany was found with the charitys help.

Abbies first transplant was in May 2020, but with the country in Covid lockdown, the stem cells had to be frozen due to restrictions.

The first transplant failed, believed in part due to the stem cells having been frozen.

The Anthony Nolan Trust stepped in and a second donor was found, but the cells were not frozen this time at the request of the hospital.

Caroline added: It is so hard when it's your child's life is suddenly put into the hands of a stranger. You're waiting for someone you don't know to come forward and help save your child's life.

The teenager underwent her second transplant in July 2020 and following a number of blood transfusions, the treatment started to work.

But due to complexities, she needed to have a top-up from her second donor at a later date.

Throughout Abbies treatment, which also included several doses of chemotherapy, radiotherapy and the top-up donation dose, she needed to stay confined in a bubble with only Caroline, dad Karl and nursing staff for company.

Abbie, of Beacon Glade, told the Gazette she felt like shed lost her purpose while receiving treatment and that losing her hair felt like the worst day of my life.

She explained: I was in denial about the whole thing. I knew I was bruising easily, but I didn't want to do anything about it. I was in denial about everything.

"I knew people lost their hair with treatment but I thought I'd be the one who didn't. Then I did and I was devastated.

I just felt like I had lost my purpose. When I lost my hair, it felt like the worst day of my life, I had had also put on quite a bit of weight.

Following her treatment and a number of blood and platelet transfusions, Abbie was finally able to ring the bell on leaving Ward 3 in August 2020; but she still needed to shield to give her body the best chance of survival.

Now, shes studying Biology, Chemistry and Psychology at A-Level and focusing on supporting the life-saving charity with her fundraising mission.

At time of writing and with weeks to go until her fundraising day at school more than 1,500 has been donated to her JustGiving page.

On her page, she said: Without you there is no cure. For someone with blood cancer, a stem cell transplant could be their last chance of survival.

Mum Caroline added: The hospital, the staff on Ward 3, were brilliant and the nurses were amazing. They were more like friends than medical professionals.

"At the time, you couldn't mix with anyone, so they were a good support to us as a family and to Abbie.

Abbie's school has also been supportive. Sir Ken, who is the school's executive head teacher, would call every day and ask how she was.

When it happened, teachers would drop off books for Abbie and they were even talking about a teacher going into a bubble, so that they could invigilate her for her GCSE exams. But the exams never happened because of Covid.

"We will be forever grateful for everyone's support.

More:
'Without you there is no cure' - Teenager's call for stem cell donors in mission to support Anthony Nolan Trust - Shields Gazette

Radical increase in the effectiveness of breast cancer immunotherapy – EurekAlert

Discovered the essential role of a new factor, LCOR, in enabling cancer cells to present tumour antigens on their surfaces

A study published in the journal Nature Cancer, carried out within the Cancer Programme at the Hospital del Mar Medical Research Institute (IMIM-Hospital del Mar) by the Cancer Stem Cells and Metastasis Dynamics Laboratory, led by Dr. Toni Celi-Terrassa, and the Laboratory of Molecular Cancer Therapy, coordinated by Dr. Joan Albanell, with the participation of international centres, has discovered an approach that radically increases the success of immunotherapy in one of the most aggressive types of tumours, triple-negative breast cancer. This subtype, although accounting for only 15% of cases, is one of the most rapidly progressing and affects younger patients. In this work, researchers found that tumour stem cells are the main cause of immunotherapy resistance in this subtype of breast cancer. The reason is that these cells are invisible to the immune system, making immunotherapy ineffective. In addition, the study offers a promising solution to this situation by using a new therapeutic approach in preclinical models that makes cancer stem cells visible to the immune system so that it can then eliminate the tumour.

This subpopulation of more aggressive cells may represent between 5% and 50% of the entire tumour population in triple-negative breast cancer. They have low levels of LCOR factor, which plays a key but previously unknown role in allowing cells to present antigens on their surface, molecules that enable the immune system to differentiate normal cells from tumour cells and attack the latter. Consequently, in the case of tumour stem cells, the low presence of this LCOR factor makes them invisible to the body's defences. As a result, these cells are resistant to breast cancer immunotherapy, which has a relatively low success rate in current clinical practice.

A mechanism that provokes treatment resistance

This ability of tumour stem cells to remain invisible to the immune system allows them to withstand immunotherapy treatment. As Dr. Toni Celi-Terrassa explains, "We have seen how, despite immunotherapy treatment, these cells survive and have the ability to generate resistance, which is linked to their ability to hide from the immune system, allowing them to evade immunotherapy."

Using mouse models, the researchers have demonstrated how this situation is reversed when the LCOR gene is activated in this type of cell, setting in motion the machinery that allows the immune system to detect the tumour. It involves reconfiguring the tumour to make it completely visible and, therefore, sensitive to immunotherapy, transforming it from invisible to visible, says Ivn Prez-Nez, a pre-doctoral researcher in the Cancer Stem Cells and Metastasis Dynamics Laboratory and first author of the study. The researchers were able to see how, by combining this approach with immunotherapy, the treatment response rate was total, and all tumours were eliminated, curing the mice in the long term. This prevents both the recurrence of cancer and the generation of resistance.

Pioneering study on the use of messenger-RNA therapy in cancer and immunotherapy

Inspired by the technology used in the design of messenger-RNA vaccines for COVID-19, the researchers decided to use a similar strategy to transport and deliver LCOR gene RNA into tumour cells and trigger its function. Biological nanovesicles, small bag-like structures formed in the cells, were developed to carry this information and were shown to do so successfully, preventing the tumour stem cells from remaining invisible.

"What we are doing is making the immune system see the tumour cell better. Unlike healthy cells, malignant cells have a much higher load of recognised 'foreign' antigens, which are not inherent to the immune system. In this way, the bodys natural defences will recognise, attack and eliminate the malignant cells, explains Dr. Celi-Terrassa. In this sense, he points out that We have discovered how to make this type of breast cancer respond to immunotherapy in preclinical models, making these cells visible thanks to the use of the antigen-presenting mechanism, thereby boosting the immunotherapy response and its efficiency.

This strategy may be applicable to other types of breast cancer tumours and other tumour types, although safety studies and clinical trials in humans are needed first. Even so, according to Dr. Joan Albanell, co-leader of the study, director of the Cancer Research Programme at IMIM-Hospital del Mar and head of the Oncology Department at Hospital del Mar, this approach does open up new possibilities. "What is important is that the experimental results demonstrate an unprecedented sensitisation of triple-negative breast cancer to immunotherapy, making resistant tumours virtually curable", says Dr Albanell, also a professor at the UPF. This unequivocally motivates us to investigate therapeutic strategies that may culminate in clinical trials, and to explore whether it could be applicable to other tumours, he concludes.

The use of LCOR in combination with immunotherapy has generated a patent and a spin-off company will be created to develop this. "The project led by Dr. Celi-Terrassa and Dr. Albanell is a paradigmatic example of research in immune therapies that will be boosted in the near future by the new Immuno-oncology Division that we are creating at the IMIM", explains Dr. Joaqun Arribas, director of the IMIM-Hospital del Mar and author of the study.

The study was made possible thanks to a CLIP grant from the US Cancer Research Institute and funding from the Carlos III Health Institute (ISCIII). Thanks also go to the Spanish Association Against Cancer (Asociacin Espaola contra el Cncer; AECC), the Fero Foundation and CIBERONC, a centre to which the two researchers who led the study also belong.

Immunotherapy in cancer and breast cancer

Immunotherapy is one of the most promising treatments for eradicating tumours and curing cancer. Unfortunately, for breast cancers it is only approved in the triple-negative breast cancer subtype, where the outcomes are still far from what is expected from immunotherapy. Making immunotherapy work in breast cancer would be a great therapeutic opportunity for the breast cancer population, making it a very good option for more advanced and metastatic cases. It should be remembered that metastatic breast cancer, despite significant and continuous advances, is still not curable in the majority of patients.

Precision diagnosis, immunotherapy, personalised medicine and cutting-edge cancer research at Hospital del Mar

At Hospital del Mar, cancer is addressed through the diagnostic tools necessary to achieve a precision diagnosis that makes it possible to plan and offer patients personalised and individualised therapeutic options according to their particular circumstances. At the same time, there is a commitment to a patient-centred care model through pioneering and benchmark work in multidisciplinary functional units specific to each type of tumour. The units, comprising professionals specialising in each cancer type, offer the best therapeutic options in a model of shared decision-making with the patient. Nurse managers guide patients through the diagnostic and therapeutic process. This quality care is combined with groundbreaking cancer research at the Hospital del Mar Medical Research Institute (IMIM) and an extensive programme of clinical trials. The research areas focus on furthering immunotherapy and liquid biopsy, searching for biomarkers and new therapeutic targets, and developing new surgery and radiotherapy strategies to improve efficacy and the quality of life of patients. This research generates almost 200 articles in scientific publications each year, two out of three of which are in high-impact journals. This state-of-the-art care and research are the basis for teaching excellence at the Hospital del Mar Campus.

Reference article

Prez-Nez I, Rozaln C, Palomeque JA, Sangrador I, Dalmau M, Comerma L, Hernndez-Prat A, Casadevall D, Menendez S, Liu DD, Shen M, Berenguer J, Rius Ruiz I, Pea R, Montas JC, Alb MM, Bonnin S, Ponomarenko J, Gomis RR, Cejalvo JM, Servitja S, Marzese DM, Morey Ll, Voorwerk L, Arribas J, Bermejo B, Kok M, Pusztai L, Kang Y, Albanell J, Celi-Terrassa T. LCOR mediates interferon-independent tumor immunogenicity and responsiveness to immune-checkpoint blockade in triple negative breast cancer. Nature Cancer (2022)https://doi.org/10.1038/s43018-022-00339-4

LCOR mediates interferon-independent tumor immunogenicity and responsiveness to immune-checkpoint blockade in triple negative breast cancer

17-Mar-2022

Original post:
Radical increase in the effectiveness of breast cancer immunotherapy - EurekAlert

Therapeutic Solutions International Successfully Treats No Option Patients with its JadiCell Stem Cell Therapy While Advancing Preparations for Phase…

Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.

Company Accelerating Clinical Progress in Response to Omicron Outbreak by Pre-Trial Implementation in Real Life Clinical Situations Leveraging Right to Try Exemption

OCEANSIDE, Calif.--(BUSINESS WIRE)-- Therapeutic Solutions International (TSOI) announced today successful treatment of 15 recent patients under the Right to Try Law with the Companys universal donor JadiCell adult stem cell product. All patients displayed no adverse events and demonstrated subjective and objective levels of improvement.

There were 12 COVID-19 patients who underwent a profound recovery despite advanced stage of disease, while the retired Navy SEAL that was previously publicly disclosed1 along with two other retired SEALS, had a significant decrease in biomarkers associated with Chronic Traumatic Encephalopathy (CTE), as well as psychological improvement at the two month follow up.

We are making progress in preparing for the upcoming Phase III clinical trial of JadiCells for treatment of COVID-19. This includes negotiation with the contract research organization, site recruitment and selection, as well as organization of trial logistics, said James Veltmeyer, Chief Medical Officer of the Company. Despite this, COVID-19 and variants of concern such as omicron, have the potential to wreak severe chaos on our healthcare system. We have literally saved lives with JadiCells and believe in making the treatment available as soon as possible under appropriate conditions.

Under the Right to Try Law, companies are allowed to provide experimental therapies that have passed Phase I clinical trials to patients who in the opinion of the physician have no therapeutic options available to them.

We plan to continue clinical implementation and data collection in a real time setting using JadiCells for patients whose physicians deem they qualify under Right to Try, said Timothy Dixon, President and CEO of Therapeutic Solutions International. Nothing makes me feel better as CEO of this Company than seeing firsthand our product saving lives. Now the mission is to make it available on a large scale, which we will.

About Therapeutic Solutions International, Inc.

Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. The Company's corporate website is http://www.therapeuticsolutionsint.com, and our public forum is https://board.therapeuticsolutionsint.com/.

1 Therapeutic Solutions International Successfully Treats Veteran Navy SEAL Suffering from Chronic Traumatic Encephalopathy with JadiCell Adult Stem Cells Under Right to Try Law

View source version on businesswire.com: https://www.businesswire.com/news/home/20211230005155/en/

Timothy G. Dixon ir@tsoimail.com

Source: Therapeutic Solutions International

Go here to read the rest:
Therapeutic Solutions International Successfully Treats No Option Patients with its JadiCell Stem Cell Therapy While Advancing Preparations for Phase...

Exclusive: Ronnie Coleman on Recent Weight Gain, Current Strength, and Health Progress – BarBend

Fans of bodybuilding are familiar with the health struggles that have plagued eight-time Mr. Olympia Ronnie Coleman in recent years. Coleman has endured over a dozen surgeries to his neck and back and, as a result, walks with crutches. Through it all, Coleman maintains a positive spirit and remains optimistic thanks in part to two stem cell treatments, which are starting to pay off.

Coleman joined co-host Giles Thomas in a recent episode of the Aint Nothing but a Podcast show. In the video, released on Dec. 29, 2021, Coleman says that hes beginning to feel like his old self again, and his weight gain reflects his health improvements.

Sporting a Ronnie Coleman Signature Series shirt that showed off his noticeable arm improvement, the Texas native his home revealed that hes back up to 285 pounds. And if youre having trouble believing that Coleman weighs close to what he did in his competitive prime, youre not alone.

I weighed myself five times on the scale downstairs, and I thought maybe its because Im downstairs,' Coleman said on the podcast episode. I was freaking out, so I went upstairs, and [that scale] was the same. I was like wow.'

BarBend reached out to the 2016 International Sports Hall of Fame inductee directly to follow up on what he revealed on his podcast. Coleman was happy to share more about his progress, including what he considers the best improvement of all the return of his signature leg size.

Thats the thing Im most proud of, Coleman tells BarBend. My legs had atrophied a whole lot since 2016 when I went in and had my first surgery 2017, same thing, 2018, 2019, 2020, same thing. I was just about to give up on it, you know. Then, suddenly, about four months ago, I started feeling a pump in my legs. And then I noticed the size had come back, and the atrophy was gone. I was geeked!

The man considered the most legendary bodybuilder of all time wasnt just known for being big. His freakish feats of strength including an 800-pound back squat and deadlift only added to the mystique he brought to the stage.

While Coleman isnt going to be moving that kind of weight anytime soon, hes been more active on social media, sharing training clips, such as the one below in which he performed a set of leg extensions on Dec. 12, 2021.

Coleman isnt leg-pressing 2,300 pounds as he did in his prime, but he is throwing more 45s on the machine nowadays than during his recovery.

Im back up to doing five plates, one each side, up from three per side a few months ago, Coleman says.

The eight-time Mr. Olympias improvements arent exclusively in the lower body. Coleman shared that hes getting stronger on numerous lifts in the gym. For example, Coleman is moving weight, performing 20 reps of rear lateral raises. The new size is evident, and his trademark smile was on full display during the set (see below).

My strength has come up a whole lot. Im going to say that its up about 40 percent.

He used the flat dumbbell press as another example, saying that he is now working with 70-pound dumbbells for his sets of 20 reps, which he does for every lift. He is training six days a week, as he did during his reign as the number one bodybuilder on the planet.

Returning leg strength is undoubtedly a strong sign that Colemans physical health is improving. That said, the former police officer mentions that itll still be a while before hes able to ditch the crutches.

My feet are still numb, and my quads are still numb, but theyre not quite as numb. I can start to feel them a little bit, he says. Once Im able to relieve this numbness, I will stand a much better chance of balancing myself.

Coleman says that the stem cell specialist told him that nerve regeneration takes about two years. As Coleman explains on the podcast, the specialists claim was verified when the numbness in his neck went away after two years, almost to the day. Coleman is confident that the same will happen with his lower extremities.

I thought about what the doctor said, and he was right. Thats what Im looking at now. It will be about two years before I get my full mobility and balance back. Then I can work on walking unassisted.

With his most recent stem cell treatment having taken place on Dec. 27, 2021, Coleman is optimistic that hell keep on progressing. This positive news caps off a good year overall for the 57-year-old icon.

In September, he was honored with the Arnold Classic Lifetime Achievement award by fellow Mr. Olympia Arnold Schwarzenegger. As great as that honor was, hes even more excited to get back out to events and meet fans now that he is in better shape and spirits I cant wait!

Featured Image: @ronniecoleman8 on Instagram

The rest is here:
Exclusive: Ronnie Coleman on Recent Weight Gain, Current Strength, and Health Progress - BarBend

Mesenchymal stem/stromal cell-based therapies for severe viral pneumonia: therapeutic potential and challenges – DocWire News

This article was originally published here

Intensive Care Med Exp. 2021 Dec 31;9(1):61. doi: 10.1186/s40635-021-00424-5.

ABSTRACT

Severe viral pneumonia is a significant cause of morbidity and mortality globally, whether due to outbreaks of endemic viruses, periodic viral epidemics, or the rarer but devastating global viral pandemics. While limited anti-viral therapies exist, there is a paucity of direct therapies to directly attenuate viral pneumonia-induced lung injury, and management therefore remains largely supportive. Mesenchymal stromal/stem cells (MSCs) are receiving considerable attention as a cytotherapeutic for viral pneumonia. Several properties of MSCs position them as a promising therapeutic strategy for viral pneumonia-induced lung injury as demonstrated in pre-clinical studies in relevant models. More recently, early phase clinical studies have demonstrated a reassuring safety profile of these cells. These investigations have taken on an added importance and urgency during the COVID-19 pandemic, with multiple trials in progress across the globe. In parallel with clinical translation, strategies are being investigated to enhance the therapeutic potential of these cells in vivo, with different MSC tissue sources, specific cellular products including cell-free options, and strategies to licence or pre-activate these cells, all being explored. This review will assess the therapeutic potential of MSC-based therapies for severe viral pneumonia. It will describe the aetiology and epidemiology of severe viral pneumonia, describe current therapeutic approaches, and examine the data suggesting therapeutic potential of MSCs for severe viral pneumonia in pre-clinical and clinical studies. The challenges and opportunities for MSC-based therapies will then be considered.

PMID:34970706 | DOI:10.1186/s40635-021-00424-5

More here:
Mesenchymal stem/stromal cell-based therapies for severe viral pneumonia: therapeutic potential and challenges - DocWire News

Brainstorm Cell Therapeutics (BCLI) Receives FDA Authorization for Expanded Dosing Program; Shares Higher – InvestorsObserver

News Home

Monday, December 27, 2021 10:53 AM | Kyle Depontes

Brainstorm Cell Therapeutics Inc. (BCLI)today announced plans for a dosing extension of NurOwn for Amyotrophic Lateral Sclerosis (ALS) participants who completed the Expanded Access Protocol (EAP).

Under the original EAP, participants who had completed the Phase 3 NurOwn trial and who met specific eligibility criteria had the opportunity to receive 3 doses of NurOwn.

Under the amended EAP, these eligible participants will receive up to 3 additional doses.

The company is also developing novel adult stem cell therapies for neurodegenerative disorders such as Progressive Multiple Sclerosis, and Parkinson's disease.

Shares of BCLI increased 1.19% to $3.76 as of Monday at 10:24am.

The expansion the Brainstorm's NurOwn trial will be an excellent opportunity for the company to test its technology through an expanded dosing program.

The NurOwn platform is a revolutionary technology that harnesses MSC-NTF cells, which are produced from autologous, bone marrow-derived mesenchymal stem cells (MSCs) to deliver multiple NTFs and immunomodulatory cytokines directly to the site of damage to stabilize disease progression.

Robert Brown, Department of Neurology Chair at the University of Massachusetts and Principal Investigator, commented,"This dosing extension for the expanded access protocol is an appropriate next step following the new analysis and biomarkers results of the Phase 3 study."

"It is deeply appreciated by our ALS patients. Eligible patients now have the opportunity to receive as many as 9 doses of NurOwn in total, allowing additional data collection to better understand the potential benefits of longer-term treatment."

According to theFDA, EAPs, alternatively known as "compassionate use" programs, provide a pathway for appropriate patients to receive an investigational medicine for treatment of a serious disease outside of a clinical trial when no satisfactory alternative therapy options are available.

BCLI has a Fundamental Rank of 77. Find out what this means to you and get the rest of the rankings on BCLI!

Brainstorm Cell Therapeutics Inc is a biotechnology company. The company is developing novel adult stem cell therapies for debilitating neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Progressive Multiple Sclerosis (PMS), and Parkinson's disease (PD). Brainstorm's NurOwn, its proprietary process for the propagation of Mesenchymal Stem Cells (MSC) and differentiation into neurotrophic factor-(NTF) secreting cells (MSC-NTF), and their transplantation at, or near, the site of damage, offers the hope of more effectively treating neurodegenerative diseases.

Friday, December 31, 2021 04:33 PM | MT Newswires

Friday, December 31, 2021 04:08 PM | MT Newswires

Friday, December 31, 2021 04:00 PM | MT Newswires

Friday, December 31, 2021 04:00 PM | MT Newswires

Friday, December 31, 2021 03:43 PM | MT Newswires

Friday, December 31, 2021 03:03 PM | MT Newswires

More here:
Brainstorm Cell Therapeutics (BCLI) Receives FDA Authorization for Expanded Dosing Program; Shares Higher - InvestorsObserver

Cell Freezing Media for Cell Therapy Market Size 2021 Analysis by Top Companies | Biolife Solutions,Thermo Fisher Scientific,Merck,Ge Healthcare …

New Jersey, United States,-Market Research Intellect has been analyzing technology and markets for Cell Freezing Media for Cell Therapy since 2018. Since then, through Research Analysis of companies, we have been very close to the latest research and market development.

In addition, Market Research Intellect works closely with many customers to help them better understand the technology and market environment and develop innovation and commercialization strategies.

Market Research Intellect offers a wealth of expertise in Cell Freezing Media for Cell Therapy Market analysis. We have been in this business for the past 20 years, and we have closely watched the rise and/or fall, success and/or disappointment of many emerging technologies during this time.

This gives us a uniquely experienced eye when it comes to analyzing emerging electronic materials technologies. This is very important because it helps build a realistic market and technology roadmap that reflects the true potential of technology based on its intrinsic characteristics and the true level of technology and commercial challenges it faces.

Get | Download Sample Copy with TOC, Graphs & List of [emailprotected]https://www.marketresearchintellect.com/download-sample/?rid=219043

In addition, market revenues based on region and country are provided in the report on Cell Freezing Media for Cell Therapys. The authors of the report also shed light on the common business tactics adopted by actors. The main players in the global bCell Freezing Media for Cell Therapy market and their full profiles are included in the report. In addition, investment opportunities, recommendations and current trends in the global Cell Freezing Media for Cell Therapy market are mapped by the report. Thanks to this report, key players in the global Cell Freezing Media for Cell Therapy market will be able to make good decisions and plan their strategies accordingly to stay ahead of the curve.

The competitive landscape is an essential aspect that every key player must know. The report highlights the competitive scenario of the global Cell Freezing Media for Cell Therapy market to know the competition at the national and global levels. The market experts also presented the broad outlines of each major player in the global Cell Freezing Media for Cell Therapy market, taking into account key aspects such as business areas, production and product portfolio. In addition, the companies in the report are studied according to key factors such as company size, market share, market growth, revenues, production volume and profits.

The major players covered in Cell Freezing Media for Cell Therapy Markets:

Cell Freezing Media for Cell Therapy Market Breakdown by Type:

Cell Freezing Media for Cell Therapy Market breakdown by application:

The Cell Freezing Media for Cell Therapy market report has been separated according to separate categories, such as product type, application, end-user, and region. Each segment is evaluated on the basis of CAGR, share, and growth potential. In the regional analysis, the report highlights the prospective region, which is expected to generate opportunities in the global Cell Freezing Media for Cell Therapys market in the coming years. This segmental analysis will surely prove to be a useful tool for readers, stakeholders and market participants in order to get a complete picture of the global Cell Freezing Media for Cell Therapys market and its growth potential in the coming years.

Get | Discount On The Purchase Of This Report @ https://www.marketresearchintellect.com/ask-for-discount/?rid=219043

Cell Freezing Media for Cell Therapy Market Report Scope

Regional market analysis Cell Freezing Media for Cell Therapy can be represented as follows:

Each regional Cell Freezing Media for Cell Therapy sectors is carefully studied to understand its current and future growth scenarios. This helps players to strengthen their position. Use market research to get a better perspective and understanding of the market and target audience and ensure you stay ahead of the competition.

The base of geography, the world market of Cell Freezing Media for Cell Therapy has segmented as follows:

Key questions answered in the report:

For More Information or Query or Customization Before Buying, Visit @ https://www.marketresearchintellect.com/product/global-cell-freezing-media-for-cell-therapy-market-size-and-forcast/

Visualize Cell Freezing Media for Cell Therapy Market using Verified Market Intelligence:-

Verified Market Intelligence is our BI-enabled platform to tell the story of this market. VMI provides in-depth predictive trends and accurate insights into more than 20,000 emerging and niche markets to help you make key revenue impact decisions for a brilliant future.VMI provides a comprehensive overview and global competitive landscape of regions, countries, and segments, as well as key players in your market. Showcase your market reports and findings with built-in presentation capabilities, providing more than 70% of time and resources for investors, sales and marketing, R & D, and product development. VMI supports data delivery in Excel and interactive PDF formats and provides more than 15 key market indicators for your market.

Visualize Cell Freezing Media for Cell Therapy Market using VMI @ hhttps://www.marketresearchintellect.com/mri-intelligence/

The study explores in depth the profiles of the main market players and their main financial aspects. This comprehensive business analyst report is useful for all existing and new entrants as they design their business strategies. This report covers production, revenue, market share and growth rate of the Cell Freezing Media for Cell Therapy market for each key company, and covers breakdown data (production, consumption, revenue and market share) by regions, type and applications. Cell Freezing Media for Cell Therapy historical breakdown data from 2016 to 2020 and forecast to 2021-2029.

About Us: Market Research Intellect

Market Research Intellect provides syndicated and customized research reports to clients from various industries and organizations in addition to the objective of delivering customized and in-depth research studies.We speak to looking logical research solutions, custom consulting, and in-severity data analysis lid a range of industries including Energy, Technology, Manufacturing and Construction, Chemicals and Materials, Food and Beverages. Etc Our research studies assist our clients to make higher data-driven decisions, admit push forecasts, capitalize coarsely with opportunities and optimize efficiency by bustling as their belt in crime to adopt accurate and indispensable mention without compromise.Having serviced on the pinnacle of 5000+ clients, we have provided expertly-behaved assert research facilities to more than 100 Global Fortune 500 companies such as Amazon, Dell, IBM, Shell, Exxon Mobil, General Electric, Siemens, Microsoft, Sony, and Hitachi.

Contact us:Mr. Edwyne Fernandes US: +1 (650)-781-4080 UK: +44 (753)-715-0008 APAC: +61 (488)-85-9400 US Toll-Free: +1 (800)-782-1768

Website: https://www.marketresearchintellect.com/

Original post:
Cell Freezing Media for Cell Therapy Market Size 2021 Analysis by Top Companies | Biolife Solutions,Thermo Fisher Scientific,Merck,Ge Healthcare ...